REGISTERED NUMBER: 06790466 (England and Wales)

CLENT LIFE SCIENCE LIMITED

UNAUDITED FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 JANUARY 2025

Page

Company Information

1

Chartered Accountants' Report

2

Statement of Financial Position

3

Notes to the Financial Statements

5

DIRECTOR:

Mr. D. Harris

REGISTERED OFFICE:

15-17 Church Street

Stourbridge

West Midlands

DY8 1LU

REGISTERED NUMBER:

06790466 (England and Wales)

ACCOUNTANTS:

Folkes Worton LLP

15-17 Church Street

Stourbridge

West Midlands

DY8 1LU

BANKERS:

Barclays Bank Plc

81 High Street

Stourbridge

West Midlands

DY8 1EB

The following reproduces the text of the report prepared for the director in respect of the company's annual unaudited financial statements. In accordance with the Companies Act 2006, the company is only required to file a Statement of Financial Position. Readers are cautioned that the Income Statement and certain other primary statements and the Report of the Director are not required to be filed with the Registrar of Companies.

In order to assist you to fulfil your duties under the Companies Act 2006, we have prepared for your approval the financial statements of Clent Life Science Limited for the year ended 31 January 2025 which comprise the Income Statement, Statement of Financial Position, Statement of Changes in Equity and the related notes from the company's accounting records and from information and explanations you have given us.

As a practising member firm of the Institute of Chartered Accountants in England and Wales (ICAEW), we are subject to its ethical and other professional requirements which are detailed within the ICAEW's regulations and guidance at http://www.icaew.com/en/membership/regulations-standards-and-guidance.

This report is made solely to the director of Clent Life Science Limited in accordance with our terms of engagement. Our work has been undertaken solely to prepare for your approval the financial statements of Clent Life Science Limited and state those matters that we have agreed to state to the director of Clent Life Science Limited in this report in accordance with ICAEW Technical Release 07/16AAF. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than Clent Life Science Limited and its director for our work or for this report.

It is your duty to ensure that Clent Life Science Limited has kept adequate accounting records and to prepare statutory financial statements that give a true and fair view of the assets, liabilities, financial position and loss of Clent Life Science Limited. You consider that Clent Life Science Limited is exempt from the statutory audit requirement for the year.

We have not been instructed to carry out an audit or a review of the financial statements of Clent Life Science Limited. For this reason, we have not verified the accuracy or completeness of the accounting records or information and explanations you have given to us and we do not, therefore, express any opinion on the statutory financial statements.

Folkes Worton LLP

15-17 Church Street

Stourbridge

West Midlands

DY8 1LU

3 June 2025

FIXED ASSETS

Tangible assets

4

82,737

89,215

Investments

5

70

70

82,807

89,285

CURRENT ASSETS

Stocks

114,061

109,896

Debtors

6

47,810

200,901

Cash at bank and in hand

89,326

117,099

251,197

427,896

CREDITORS

Amounts falling due within one year

7

679,109

328,451

NET CURRENT (LIABILITIES)/ASSETS

(427,912

)

99,445

TOTAL ASSETS LESS CURRENT LIABILITIES

(345,105

)

188,730

PROVISIONS FOR LIABILITIES

-

16,951

NET (LIABILITIES)/ASSETS

(345,105

)

171,779

CAPITAL AND RESERVES

Called up share capital

1

1

Retained earnings

(345,106

)

171,778

SHAREHOLDERS' FUNDS

(345,105

)

171,779

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31 January 2025.

The members have not required the company to obtain an audit of its financial statements for the year ended 31 January 2025 in accordance with Section 476 of the Companies Act 2006.

The director acknowledges his responsibilities for:

(a)	ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and

(b)

preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Income Statement has not been delivered.

The financial statements were approved by the director and authorised for issue on 3 June 2025 and were signed by:

Mr. D. Harris - Director

1.	STATUTORY INFORMATION

Clent Life Science Limited is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

2.	ACCOUNTING POLICIES

Basis of preparing the financial statements

These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Turnover

Turnover represents net sales of goods/services, excluding value added tax

Tangible fixed assets

Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.

Plant and machinery

-

15% on reducing balance

Fixtures and fittings

-

15% on reducing balance

Motor vehicles

-

25% on reducing balance

Computer equipment

-

33% on reducing balance

Investments in subsidiaries

Investments in subsidiary undertakings are recognised at cost.

Stocks

Stocks are valued at the lower of cost and net realisable value, after making due allowance for obsolete and slow moving items.

Taxation

Taxation for the year comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the statement of financial position date.

Deferred tax

Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the statement of financial position date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

Pension costs and other post-retirement benefits

The company operates a defined contribution pension scheme. Contributions payable to the company's pension scheme are charged to profit or loss in the period to which they relate.

3.	EMPLOYEES AND DIRECTORS

The average number of employees during the year was 8 (2024 - 8 ) .

4.	TANGIBLE FIXED ASSETS

Fixtures

Plant and

and

Motor

Computer

machinery

fittings

vehicles

equipment

Totals

£

£

£

£

£

COST

At 1 February 2024

32,420

43,136

38,500

7,727

121,783

Additions

8,100

1,095

-

2,044

11,239

Disposals

-

(100

)

-

-

(100

)

At 31 January 2025

40,520

44,131

38,500

9,771

132,922

DEPRECIATION

At 1 February 2024

11,672

10,794

4,010

6,092

32,568

Charge for year

3,316

4,864

8,623

814

17,617

At 31 January 2025

14,988

15,658

12,633

6,906

50,185

NET BOOK VALUE

At 31 January 2025

25,532

28,473

25,867

2,865

82,737

At 31 January 2024

20,748

32,342

34,490

1,635

89,215

5.	FIXED ASSET INVESTMENTS

Shares in

group

undertakings

£

COST

At 1 February 2024

and 31 January 2025

70

NET BOOK VALUE

At 31 January 2025

70

At 31 January 2024

70

6.

DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

2025

2024

£

£

Trade debtors

16,017

29,748

Amounts owed by group undertakings

17,764

89,764

Other debtors

14,029

81,389

47,810

200,901

7.

CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

2025

2024

£

£

Trade creditors

42,970

4,832

Amounts owed to group undertakings

617,462

263,040

Taxation and social security

10,325

49,632

Other creditors

8,352

10,947

679,109

328,451

8.	ULTIMATE CONTROLLING PARTY

The company is controlled by Mr. D. Harris by virtue of his 100% shareholding in the parent company, Clent Life Holdings Limited.